Skip to main content

You are here

Magdia De Jesus, Ph.D.

  • Magdia De Jesus, Ph.D.

    Magdia De Jesus, Ph.D.

    • Mucosal Immunology
    • Assistant Professor, Department of Biomedical Sciences, School of Public Health, University at Albany
    • Research Scientist, Wadsworth Center

    • Ph.D., Albert Einstein College of Medicine (2009)
    • Postdoctoral training: CDC/APHL EID Research Fellow, Wadsworth Center (2009-2011)
    • Postdoctoral training: Life Science Research Foundation-HHMI, Wadsworth Center (2011-2014)

    magdia.dejesus@health.ny.gov


Research Interests

Although a commensal and a part of the natural human mycobiome, increased colonization of the gastrointestinal tract with Candida albicans has been associated with a number of human gastrointestinal (GI) tract associated diseases such as gastric ulcers, familial Crohn’s disease and Hirschsprung-associated enterocolitis. The De Jesus laboratory is interested in elucidating gut-fungal interactions as well as the development of systemic and mucosal against C. albicans.

Candida albicans:

  1. Understanding the basic immunological parameters that govern how the intestinal mucosa recognize fungi such as C. albicans
    1. How do intestinal Peyer’s patches recognize C. albicans?
    2. What is the specific role of Peyer’s patch mononuclear phagocytes in the recognition and presentation of C. albicans?
    3. What are the specific innate immune signals that “set off the alarms” when C. albicans is sampled?
  2. Development of vaccines against C. albicans
    1. Development of anti-C. albicans mucosal and systemic vaccines using β-glucan microparticle delivery vehicles

Candida auris:

As an emerging fungal pathogen, Candida auris has become a serious global public health threat due to its resistance to an already limited arsenal of antifungals such as fluconazole, voriconazole and itraconazole, and its reduced susceptibility to amphotericin B. Although C. auris was discovered in 2009, it has spread quickly to over a dozen countries. Persistence of C. auris in nosocomial and nursing home settings is of particular concern; as C. auris can cause invasive bloodstream infections with a high fatality rate of 60%.

  1. Development of reproducible animal models of C. auris
    1. Elucidate the pathogenesis of C. auris in mice
  2. Development of vaccines against C. auris
    1. Development of anti- C. auris mucosal and systemic vaccines using β-glucan microparticle delivery vehicles.

To learn more, please visit the De Jesus Laboratory.

Select Publications

Singh N, Gallagher HC, Song R, Dhinsa JK, Ostroff GR, De Jesus M.
RNA isolation from Peyer’s patch lymphocytes and mononuclear phagocytes to determine gene expression profiles using nanostring technology.
Journal of Biological Methods.
(2018)
De Jesus M, Rodriguez AE, Yagita H, Ostroff GR, Mantis NJ.
Sampling of Candida albicans and Candida tropicalis by Langerin-positive dendritic cells in mouse Peyer's patches.
Immunology Letters.
(2015)
168
(1):
64-72.
De Jesus M, Ostroff GR, Levitz SM, Bartling TR, Mantis NJ.
A population of Langerin-positive dendritic cells in murine Peyer's patches involved in sampling β-glucan microparticles.
PLoS One.
(2014)
9
(3):
e91002.
Ahlawat S, De Jesus M, Khare K, Cole RA, Mantis NJ.
Three-dimensional reconstruction of murine Peyer's patches from immunostained cryosections.
Microsc Microanal.
(2014)
20
(1):
198-205.
De Jesus M, Ahlawat S, Mantis NJ.
Isolating and immunostaining lymphocytes and dendritic cells from murine Peyer's patches.
J Vis Exp.
(2013)
(73):
50167.